Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
Abstract Advances in cancer immunology have increased the use of immune checkpoint inhibitors in clinical practice, however not all patients respond, and treatment can have severe side-effects. Blood-based immunological biomarkers are an attractive method for predicting which patients will respond t...
Guardado en:
Autores principales: | Sarah J. Dart, Alistair M. Cook, Michael J. Millward, Alison M. McDonnell, Wee L. Chin, Muhammad U. Hakeem, Tarek M. Meniawy, Samantha E. Bowyer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9d283bf0f1db4f83be33e5ef052e4ddd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
por: KE Ping, et al.
Publicado: (2021) -
Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao M, et al.
Publicado: (2015) -
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
por: Douglas B. Johnson, et al.
Publicado: (2016) -
Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021) -
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Hyun Tae Lee, et al.
Publicado: (2017)